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Abstract: To determine the prevalence of influenza vaccination in chronic obstructive pulmonary
disease (COPD) patients and its effect on COPD exacerbations, we conducted a retrospective
population-based cohort study analyzing real-life data. We included all registered COPD patients
≥40 years old using respiratory medication during the study period (2012–2013). Influenza vaccination
during the 2012/2013 campaign was the parameter studied. Moderate and severe exacerbations
during 2013 were the dependent outcome variables. Logistic regression adjusting for age, gender,
concomitant asthma diagnosis, COPD severity, smoking status, number of moderate and severe
exacerbations the previous year, and comorbidities was performed, and 59.6% of the patients received
seasonal influenza vaccination. The percentage of patients with exacerbations was higher among those
vaccinated. Influenza vaccination had a statistically significantly negative (non-protective) crude effect
favoring the risk of severe exacerbations: OR: 1.20 (95% CI; 1.05–1.37). This association diminished
and lost statistical significance after adjustment: aOR: 0.93 (95% CI; 0.74–1.18). The protective effect
in the analysis restricted to the epidemic period was not significant: aOR: 0.82 (95% CI; 0.58–1.16).
We concluded that prevalence of influenza vaccination was suboptimal. In contrast with most of the
available evidence, our results did not support a protective effect of influenza vaccination on the risk
of admission for COPD exacerbation.
Keywords: chronic obstructive pulmonary disease; influenza vaccination; COPD exacerbations;
primary prevention
1. Introduction
Chronic obstructive pulmonary disease (COPD) prevalence is increasing over time. It is the fourth
leading cause of death in the world and it will be the third by 2021. COPD exacerbations are episodes of
temporary symptom worsening (e.g., breathlessness, cough, sputum production) that carry significant
consequences for patients [1,2] Additionally, exacerbations are associated with an accelerated rate of
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lung function decline, reduced quality of life, and an increased mortality risk [3]. COPD exacerbations
are heterogeneous and dependent on multiple risk factors [4]; however, generally, their frequency and
severity increase as the disease worsens [5].
The fact that COPD exacerbations can be associated with influenza is of great public health
interest. The most frequent causes of exacerbations are respiratory infections, most of them viral.
In particular, influenza can be a causative virus for exacerbations, of which the more severe ones
result in hospital admissions and even death [6,7]. Two systematic reviews recently analyzed the
effectiveness of seasonal influenza vaccination in patients with COPD, concluding that the evidence
supports a positive benefit–risk ratio for seasonal influenza vaccination in these patients, although
most of the included trials were more than a decade old [8,9]. Considering the role of influenza in
contributing to COPD exacerbations, the associated complications, and their related healthcare costs,
immunization against influenza is recommended for all patients with COPD by major agencies and
guidelines [1,10,11].
Despite influenza vaccination being recommended, vaccination rates are highly variable among
different countries, including Spain [12–17], with further room for improvement [18]. On the one hand,
those COPD patients who are likely to exacerbate could have more motivation to accept influenza
vaccination [16,17]. On the other hand, vaccination rejection among COPD patients has been attributed
to concerns about increased exacerbations or adverse reactions caused by the vaccine itself [13,16].
There are also many knowledge gaps regarding the impact of COPD severity and co-morbidity on
influenza vaccine effectiveness. Therefore, additional studies are required [6,9].
Our primary aim is to determine the prevalence of influenza vaccination in COPD patients in
a real-life population cohort in the Balearic Islands (Spain) and the association between history of
influenza vaccination and COPD exacerbations.
2. Materials and Methods
Study design: Retrospective cohort study analyzing real-life data from the COPD population of
the MAJOrca Real-world Investigation in COPD and Asthma cohort (MAJORICA-cohort). We reported
our findings in line with Strengthening the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines for observational studies using routinely collected health data [19].
Data source: The MAJORICA-cohort contains data from all patients (≥18 years) with a primary
care diagnosis of asthma and/or COPD in 2012 (N = 68,578), irrespective of health insurance, with at
least two years follow-up available. Most recent follow-up data are from 2015. The cohort data are
anonymously collected from the unique primary care system (eSIAP), all hospital systems, as well as
the electronic prescription system (RELE) in the Balearic Islands, Spain [20–22].
Study population: Among the overall MAJORICA-cohort, patients who were using respiratory
medication (ATC (Anatomical Therapeutic Chemical) code: R03) in 2012, 2013, and 2014 were firstly
selected. From the included sample, all patients who had a physician diagnosis of COPD (ICD-9
codes: 491, 492, and/or 496) and were over 40 years of age were identified as patients with actively
treated COPD.
Exposure: Patients were classified in two cohorts (exposed versus non-exposed) according to
whether or not they had received influenza vaccination in the 2012–2013 campaign (between 18 October
and 30 November 2012).
Outcome: The outcome of interest was COPD exacerbation. COPD exacerbation was defined as any
episode involving an increase in patient’s baseline COPD symptoms (cough, pleghms, and/or dyspnea),
requiring the prescription of an antibiotic and/or systemic corticosteroid (moderate exacerbation),
or hospital admission for more than 24 h (severe exacerbation) [23,24]. The total frequency of
exacerbations (moderate and severe) was quantified in 2012 and 2013. In a sensitivity analysis,
exacerbations that occurred during the 2013 influenza epidemic seasonal period in our setting
(7 January 2013 to 31 March 2013) [25] were also identified and quantified as a specific variable.
In order to differentiate a new exacerbation from a previous treatment failure, each exacerbation had
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to be separated for at least 6 weeks from previous exacerbation initial treatment or 4 weeks from
hospital discharge.
Co-variates: At baseline, for each patient, sociodemographic and clinical characteristics were
collected, including sex, age, smoking habit, COPD obstruction severity (by GOLD grades 1–4),
relevant comorbidities, respiratory treatments, and number and severity of COPD exacerbations in
the previous year in order to identify the exacerbation “phenotype”. “Exacerbator phenotype” was
defined as a patient who suffered from at least two moderate exacerbations or one severe exacerbation
in a one-year period according to the main national and international guidelines definition [1,16,23,26].
“Non-exacerbator phenotype” patients were those having ≤1 moderate exacerbation and no severe
exacerbations in a one-year period.
Statistical analyses: For categorical and discrete variables, proportions were estimated
using Pearson’s Chi-squared tests for comparisons or Fisher’s exact tests when necessary.
Quantitative variables were expressed as mean and standard deviation (SD) using the student’s t-test
for comparisons after normal distribution was confirmed using the Shapiro–Wilk test. Dichotomous
values (“at least one admission for COPD exacerbation”, “at least one moderate COPD exacerbation”,
and “exacerbator phenotype or not” during the following year) were treated as dependent (effect)
variables. To assess the crude univariate association between influenza vaccination and the risk of
COPD exacerbations, crude odds ratios (OR) were estimated using unconditional logistic regression
with 95% confidence intervals (95% CI). Non-vaccinated COPD patients were the reference category.
Thus, an OR greater than one indicates that the vaccine is a risk factor for exacerbations. An OR less than
one indicates that vaccination is protective, and an OR equal to one indicates a null effect on the risk of
exacerbations the following year. To control for confounding bias, we predefined confounders related
with the exposure (vaccination) and/or the outcome (exacerbations) in a stepwise regression analysis.
The co-variables finally included were age (continuous variable), gender, concomitant asthma diagnosis,
COPD severity (GOLD grades 1–4), smoking status (ordinal variable: non-smoker, former smoker,
current smoker), number of moderate exacerbations in the previous year, number of severe exacerbations
in the previous year, and the following comorbidities: heart failure, atrial fibrillation, cor pulmonale,
anxiety, osteoporosis, allergic rhinitis, gastroesophageal reflux disease, and diabetes. Associations
were stratified according to COPD severity based on forced expiratory volume in one second (FEV1%)
predicted (GOLD grades 1–4) and restricted to patients with spirometry confirmed COPD (FEV1/FVC
(Forced Vital Capacity) < 0.7) in a sensitivity analysis. We set the alpha error at 0.05, and all p-values
were bilateral. All statistical analyses were performed using IBM SPSS Statistics, version 22.0 (IBM,
New York, NY, USA).
Ethics: The study protocol PI17-07 was approved by the Primary Care Research Committee of
Mallorca. All data came from real-life clinical files, but they were anonymized for analysis, making it
impossible to identify individual patients.
3. Results
3.1. Population Characteristics
The flow chart for selecting study patients is shown in Figure 1 (R03 = respiratory medication).
In total, 12,396 patients fulfilled all study inclusion/exclusion criteria. Most patients were
men (67.3%), overall mean age was 69.7 years, almost one third were current smokers, mean FEV1
(% predicted) was 62.7, and 24% were frequent exacerbators. Patients’ sociodemographic and clinical
variables are shown in Table 1.
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Table 1. Main sociodemographic and clinical variables in relation to influenza vaccination during
2012/2013 seasonal campaign.
Unvaccinated Vaccinated Total
N = 5003 % Row N = 7393 % Row N = 12,396 % column p Value
Sex
Women 1884 46.4% 2174 53.6% 4058 32.7% <0.001
Men 3119 37.4% 5219 62.6% 8338 67.3%
Age
Mean [SD] 66.56 11.52 71.884 10.08 69.735 11 <0.001
BMI
Mean [SD] 29.93 6.38 30.17 7.94 30.09 7.42 0.003
Normal weight (18.5–24.9) 594 41.1% 850 58.9% 1444 16.90% * <0.001
Overweight (25–29.9) 1045 34.1% 2019 65.9% 3064 35.80%
Obesity (≥30) 1381 34.8% 2583 65.2% 3964 46.30%
Underweight (<18.5) 43 48.9% 45 51.1% 88 1.00%
Missing values 1940 50.6% 1896 49.4% 3836 30.9%
BMI > 21 2903 35.3% 5311 64.7% 8214 96.00% <0.001
BMI ≤21 160 46.2% 186 53.8% 346 4.00%
Missing values 1940 50.6% 1896 49.4% 3836 30.9%
Smoking habit
Never 1233 34.2% 2368 65.8% 3601 32.30% * <0.001
Former 1439 32.9% 2930 67.1% 4369 39.20%
Current 1735 54.6% 1443 45.4% 3178 28.50%
Missing values 596 47.8% 652 52.2% 1248 10.1%
FEV1
Mean [SD] 64.19% 19.56 61.74% 19.79 62.66% 19.74 <0.001
Obstruction severity (FEV1)
GOLD 1 (≥80%) 467 42.5% 633 57.53% 1100 19.60% * <0.001
GOLD 2 (≥50–80%) 1133 37.8% 1862 62.2% 2995 53.40%
GOLD 3 (≥30–49.9%) 449 33.7% 884 66.3% 1333 23.80%
GOLD 4 (<30%) 64 35.0% 119 65.0% 183 3.30%




mean [SD] 0.7 1 0.84 1.09 0.78 1.06 <0.001
None (0 exacerbations) 2800 43.0% 3714 57.0% 6514 52.5%
1 exacerbation 1332 38.9% 2096 61.1% 3428 27.7%




admissions, mean [SD] 0.08 0.34 0.1 0.39 0.09 0.37 0.003
None (0 COPD admissions) 4648 40.7% 6763 59.3% 11411 92.1% 0.01
1 COPD admission 292 36.5% 509 63.5% 801 6.5%




mean [SD] 0.79 1.15 0.94 1.26 0.88 1.22 <0.001
None (0 exacerbations) 2737 43.1% 3614 56.9% 6351 51.2% <0.001
1 exacerbation 1254 38.6% 1993 61.4% 3247 26.2%
≥2 exacerbations 1012 36.2% 1786 63.8% 2798 22.6%
Exacerbator phenotype 2012
No 3931 41.6% 5514 58.4% 9445 76.2% <0.001
Yes 1072 36.3% 1879 63.7% 2951 23.8%
* Valid percentage, excluding the missing values. BMI: body mass index, FEV1 forced expiratory volume in one
second, COPD: chronic obstructive pulmonary disease. GOLD: Global Initiative for Obstructive Pulmonary Disease
obstruction grades.
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Figure 1. Flow chart for selection of study sample.
3.2. Prevalence and Characteristics of Influenza Vaccination
Overall, the influenza vaccination coverage in COPD patients was 59.6% (7393/12396).
A comparison between vaccinated and non-vaccinated patients is presented in Table 1. The vaccination
rate was slightly higher in men (62.6%) than women (53.6%), and vaccinated subjects were older
than those non-vaccinated (71.9 versus 66.6 years, p < 0.001). There were also statistically significant
differences in vaccination coverage as a function of BMI or smoking habit. Vaccination rates were slightly
higher in more severe COPD patients (65.0% in GOLD 4) in comparison with milder obstructive ones
(57.5% in GOLD 1). Vaccination coverage was also hi her in patients with a history of moderate and/or
severe exacerbations in 2012 (the same year of vaccination) compared to those with no exacerbations
during the previous year. Sufferi g from each of the a alyzed comorbidities was also associated with
higher influenza vaccination coverage (Table 1). Main comorbidities in relation to influenza vaccination
are described in Supplementary Table S1.
3.3. Effects of Influenza Vaccination on COPD Exacerbations
Table 2 shows a descriptive analysis of the history of exacerbations (primary effect endpoint)
during the following year as a function of influenza vaccination. The percentage of patients who
suffered from moderate and/or severe exacerbations was higher among those vaccinated.
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Table 2. Influenza vaccination during the 2012/2013 campaign and exacerbations during the
following year.
Unvaccinated Vaccinated Total
N = 5003 % N = 7393 % N = 12,396 % p Value
Moderate COPD exacerbations 2013
Number of exacerbations.
None (0 exacerbations) 2750 55.0% 3640 49.2% 6390 51.5% <0.001
1 exacerbation 1279 25.6% 1943 26.3% 3222 26.0%
≥2 exacerbations 974 19.5% 1810 24.5% 2784 22.5%
Severe COPD exacerbations 2013
Number of COPD admissions.
None (0 COPD admissions) 4618 92.3% 6722 90.9% 11340 91.5% 0.003
1 COPD admission 320 6.4% 522 7.1% 842 6.8%
≥2 COPD admissions 65 1.3% 149 2.0% 214 1.7%
Overall COPD exacerbations 2013
Number of exacerbations.
None (0 exacerbations) 2701 54.0% 3564 48.2% 6265 50.5% <0.001
1 exacerbation 1187 23.7% 1815 24.6% 3002 24.2%
≥2 exacerbations 1115 22.3% 2014 27.2% 3129 25.2%
Exacerbator phenotype 2013
No 3842 76.8% 5311 71.8% 9153 73.8% <0.001
Yes 1161 23.2% 2082 28.2% 3243 26.2%
Influenza vaccination had a statistically significant negative (non-protective) crude effect favoring
the risk of severe exacerbations: OR 1.20 (95% CI; 1.05–1.37). However, the association was towards
the null effect (losing statistical significance) after adjusting for the main confounding variables:
ORa 0.93 (95% CI; 0.74–1.18). After restricting to the 2013 influenza epidemic period, a non-significant
protective effect against the risk of severe exacerbations was observed: ORa 0.82 (95% CI; 0.58–1.16).
After stratifying according to GOLD obstruction severity (GOLD 1–4), a statistically significant negative
(non-protective) adjusted effect seemed to be observed in the most severe patients, although statistical
significance was not yielded when computing the 2013 influenza epidemic period only (Table 3).
Table 3. Crude and adjusted associations between “History of Influenza Vaccination during 2012–2013
campaign” and risk of “Admission due to COPD Exacerbation” in all patients with a diagnosis of
COPD by obstruction severity during the complete year and the epidemic period.
Severe Exacerbations (Admitted for COPD Exacerbation)
2013 Complete Year 2013 Epidemic Period Only
None At Least One None At Least One
N= 11,340 N = 1056 OR (95% CI) ORa (95% CI) N = 11,997 N = 399 OR (95% CI) ORa (95% CI)
All COPD
(N = 12,396)
Unvaccinated 4618 385 1 – 1 – 4846 157 1 – 1 –
Vaccinated 6722 671 1.20 (1.05–1.37) 0.93 (0.74–1.18) 7151 242 1.05 (0.85–1.28) 0.82 (0.58–1.16)
GOLD 1 (N = 1100)
Unvaccinated 448 19 1 – 1 – 461 6 1 – 1 –
Vaccinated 603 30 1.17 (0.65–2.11) 0.87 (0.45–1.69) 623 10 1.23 (0.45–3.42) 0.94 (0.31–2.84)
GOLD 2 (N = 2995)
Unvaccinated 1050 83 1 – 1 – 1095 38 1 – 1 –
Vaccinated 1741 121 0.88 (0.66–1.18) 0.72 (0.52–1.00) 1813 49 0.78 0.51–1.20 0.71 0.44–1.16)
GOLD 3 (N = 1333)
Unvaccinated 398 51 1 – 1 – 428 21 1 – 1 –
Vaccinated 757 127 1.31 (0.93–1.85) 1.07 (0.71–1.61) 842 42 1.02 (0.59–1.74) 0.78 (0.42–1.44)
GOLD 4 (N = 183)
Unvaccinated 55 9 1 – 1 – 60 4 1 – 1 –
Vaccinated 91 28 1.88 (0.83–4.28) 6.09 (1.77–20.97) 109 10 1.38 (0.41–4.58) 2.17 0.40–11.73
OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis,
smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations
the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure,
atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease,
and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
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Similar results were obtained restricting the analysis to patients with spirometry confirmed COPD
(FEV1/FVC < 0.7), showing a null effect (non-negative, non-positive): ORa 0.97 (95% CI; 0.74–1.27) for
the complete year, and ORa 0.81 (95% CI; 0.54–1.22) when the 2013 influenza epidemic period was
analyzed (Supplementary Table S2).
A non-significant slightly negative (non-protective) association between influenza seasonal
vaccination and COPD moderate exacerbations was found in both the 2013 complete year and in the
influenza epidemic period (Table 4).
Table 4. Crude and adjusted associations between “History of Influenza Vaccination” and risk of
moderate COPD Exacerbations” in all patients with a diagnosis of COPD by obstruction severity during
the complete year and the epidemic period.
Moderate Exacerbations
2013 Complete Year 2013 Epidemic Period Only
None At LeastOne None
At Least
One
N = 6390 N = 6006 OR (95% CI) ORa (95% CI) N = 9345 N = 3045 OR (95% CI) ORa (95% CI)
Influenza Vaccination
(N = 12,396)
Unvaccinated 2750 2253 1 – 1 – 3891 1112 1 – 1 –
Vaccinated 3640 3753 1.26 (1.17–1.35) 1.10 (0.97–1.24) 5460 1933 1.24 (1.14–1.35) 1.11 (0.96–1.28)
GOLD 1 (N = 1100)
Unvaccinated 285 182 1 – 1 – 383 84 1 – 1 –
Vaccinated 329 304 1.45 (1.14–1.84) 1.21 (0.91–1.61) 475 158 1.52 (1.13–2.04) 1.33 (0.95–1.86)
GOLD 2 (N = 2995)
Unvaccinated 648 485 1 – 1 – 892 241 1 – 1 –
Vaccinated 964 898 1.25 (1.07–1.44) 1.11 (0.93–1.31) 1404 458 1.21 (1.01–1.44) 1.05 (0.86–1.28)
GOLD 3 (N = 1333)
Unvaccinated 203 246 1 – 1 – 323 126 1 – 1 –
Vaccinated 388 496 1.06 (0.84–1.33) 0.84 (0.65–1.09) 606 278 1.18 (0.92–1.51) 1.00 (0.75–1.33)
GOLD 4 (N = 183)
Unvaccinated 37 27 1 – 1 – 47 17 1 – 1 –
Vaccinated 45 74 2.25 (1.21–4.19) 4.54 (1.77–11.67) 77 42 1.51 (0.77–2.95) 3.93 1.39–11.13
OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis,
smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations
the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure,
atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease,
and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
Similar results were shown in patients with spirometry confirmed COPD (FEV1/FVC < 0.7)
(Supplementary Table S3). However, in very severe obstructive GOLD 4 patients, the non-protective
effect was higher and statistically significant—ORa 4.54 (95% CI; 1.77–11.67) for the 2013 complete
year—and an ORa 3.93 (95% CI; 1.39–11.13) was also obtained after computing the epidemic period only
(Table 4), with similar results when restricting to spirometry confirmed COPD patients (Supplementary
Table S3).
When the effect was computed as being “exacerbator phenotype or not”, that is, suffering from at
least two moderate and/or severe exacerbations, an adjusted null effect of vaccination was observed
in the overall population, and a negative (non-protective) effect was observed when restricting to
very severe GOLD grade 4 patients (ORa 3.72 (95% CI; 1.48–9.33) (Table 5)) with similar results when
restricting to spirometry confirmed COPD patients (Supplementary Table S4).
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Table 5. Crude and adjusted associations between “History of Influenza Vaccination” and risk of being
“Frequent exacerbator phenotype” the following year in all patients with a diagnosis of COPD by
obstruction severity.
2013 Frequent Exacerbator Phenotype
No Yes




Unvaccinated 3842 1161 1 – 1 –
Vaccinated 5311 2082 1.30 (1.19–1.41) 1.02 (0.88–1.19)
GOLD 1 (N = 1100)
Unvaccinated 384 83 1 – 1 –
Vaccinated 488 145 1.38 (1.02–1.86) 1.15 (0.80–1.63)
GOLD 2 (N = 2995)
Unvaccinated 876 257 1 – 1 –
Vaccinated 1409 453 1.10 (0.92–1.31) 0.91 (0.74–1.12)
GOLD 3 (N = 1333)
Unvaccinated 315 134 1 – 1 –
Vaccinated 569 315 1.30 (1.02–1.66) 1.03 (0.77–1.39)
GOLD 4 (N = 183)
Unvaccinated 41 23 1 – 1 –
Vaccinated 65 54 1.48 (0.79–2.77) 3.72 (1.48–9.33)
OR: crude odds ratio. ORa: odds ratio adjusted for age (continuous variable), gender, concomitant asthma diagnosis,
smoking status (ordinal variable: non-smoker, former smoker, current smoker), number of moderate exacerbations
the previous year, number of severe exacerbations the previous year, and the following comorbidities: heart failure,
atrial fibrillation, cor pulmonale, anxiety disorder, osteoporosis, allergic rhinitis, gastroesophageal reflux disease,
and diabetes. COPD obstruction severity: GOLD 1: mild; GOLD 2 moderate; GOLD 3: severe; GOLD 4 very severe.
4. Discussion
Our results suggest that influenza vaccination in this concrete campaign (2012/2013) did not have
a protective effect on the risk of severe and/or moderate exacerbations in the following year, not even if
restricting the analysis to the epidemic influenza period only.
The absence of a preventive effect of seasonal influenza vaccination on moderate exacerbation
risk is also supported by previous studies. However, in contrast to our results, no previous studies
have shown an increased risk for severe exacerbations in very severe COPD patients after vaccination.
In the recently published Spanish [16,17] or international studies [9,27], a protective effect on risk for
severe exacerbations (admission for COPD exacerbation) or all-cause admissions was observed in those
receiving seasonal vaccination. The higher protective effect being previously shown for the most severe
COPD patients (GOLD 4) [17] is not supported by our results, given we found the opposite effect.
The influenza strains contributing to epidemics vary annually, and they influence the severity and
the length of the epidemic seasonal period. Vaccination impact is supposed to be greater in seasons
in which circulating strains match those used in vaccination schemes and lower in poorly matched
seasons or so-called mismatched seasons. Influenza activity in Spain in the 2012–2013 season was
moderate and was associated with a majority circulation of seasonal influenza B virus with a lower
contribution of A(H1N1) virus throughout the pandemic wave [25]. The circulating viruses were
consistent with the strains included in the 2012–2013 season vaccine for the northern hemisphere,
except for the B viruses of the Victoria lineage not included in the vaccine recommended for the
2012–2013 season. However, the B viruses of the Victoria lineage circulated in minority, thus a lack
of efficacy or mismatched vaccine would not explain the lack of preventive results in our study [25].
Since the 1996–1997 season, the influenza B virus has circulated predominantly in Spain in just two
seasons, 2002–2003 and ten years later in 2012–2013. On the other hand, the 2012–2013 season had a late
Int. J. Environ. Res. Public Health 2020, 17, 4027 9 of 12
presentation compared to the previous ones, with an epidemic peak in mid-February. Although the
epidemic wave was similar to the previous year, the 2012–2013 season was characterized by a prolonged
period of intense flu virus circulation, with a percentage of flu-positive samples remaining above 50%
for eleven consecutive weeks [25,28]. Regarding the immunogenicity of seasonal influenza vaccines
in COPD patients, the seroconversion rates ranged from 34.4 to 61.3% for influenza B in published
studies [29,30], being lower than the seroconversion rates for A/H1N1 (43 to 80.0%) or A/H3N2 (53.1 to
84.1%). Sero-protection rates for influenza B are also the lowest [9]. To what extent these peculiarities
with respect to previous seasons could explain our results may deserve further attention.
The overall influenza vaccination coverage in the 2012–2013 campaign was 59.6%. This sub-optimal
coverage is similar to those generally reported in developed countries, including Spain [12,13,17,31].
In our study, in line with other authors [16,17,32], we found that patients with several co-morbidities
had greater vaccination coverage. It should also be mentioned that vaccination coverage among
smokers was lower than among non-smokers, as also reported in other studies [16,17,33,34].
Vaccination rejection among COPD patients has been attributed to concerns about increased
exacerbations or adverse reactions caused by the vaccine itself, which could explain the rejection,
even among those with the more severe disease [13,16,34]. However, a greater incidence of exacerbation
in the early weeks after vaccination was previously ruled out [35,36], and evidence for the safety of the
vaccine seems to be conclusive [9].
Our study has several limitations.
Only a single influenza season (2012–2013) was studied. Looking at other seasons, especially those
where recommended vaccine formulations more closely matched circulating virus strains, is needed to
fully understand our observations. Similarly, data on serious influenza-related complications in the
general population (vaccinated vs. unvaccinated) need to be taken into consideration.
Our study population was selected under the criterion that they should have used respiratory
medication during the years of follow-up. This has advantages because it represents a population with
active and relevant COPD. On the other hand, it makes it impossible, for example, to study mortality
as a dependent variable in relation to influenza vaccination. A differential survival bias based on
vaccination status could be a source of selection bias. If unvaccinated people had higher mortality and
exacerbated more, the bias would underestimate the preventive effect of the vaccine. If, on the other
hand, vaccinated patients, because they have more comorbidities or are older, die and exacerbate more,
the bias would be in favor of the protective effect of the influenza vaccine.
The process for classifying record information into the outcome (i.e., moderate or severe
exacerbations) was carried out by two physicians who were blinded to the influenza vaccination status
of the study subjects. As the classification of the outcome was blinded to the exposed/non-exposed
status of the study subjects, any misclassification of the outcome would have been non-differential
towards the null association. It could be also a source of explanation for our results.
External validity is one of the main classical limitations of clinical trials, and this problem can also
affect observational studies based on small samples [37–39]. A major strength of the present study is
the inclusion of the entire population, that is, all patients diagnosed with COPD in the Balearic Islands,
Spain, (+/− 1.1 million subjects) receiving primary health care and current treatment. This provides a
useful COPD cohort representative for real-life care. It is improbable that bias arose through lack of
blindness among patients’ care providers (they treated the patients blinded retrospectively before the
development of the study). Another advantage is that we attempted to obtain the independent effect of
flu vaccination in our epidemiological and statistical approach by controlling for potential confounding.
On the other hand, as with many registers and database studies, our data were collected from
day-to-day clinical practice registers not specifically designed for the present study, and data collection
was not under the researchers’ control. Therefore, some unmeasured variables could have confounded
the results. Additionally, COPD misdiagnosis could promote a high risk of selection bias. To minimize
selection bias, we performed a sensitivity analysis by restricting to only spirometry confirmed COPD
cases, and we obtained similar results in this analysis.
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5. Conclusions
The prevalence of influenza vaccination was suboptimal in the Balearic Islands (Spain). In contrast
with the available evidence, our results did not support a protective effect of influenza vaccination on
the risk of COPD exacerbations during the following year or even during the epidemic influenza season.
A majority circulation of seasonal influenza B virus in the 2012–2013 season in Spain, with respect to
previous seasons, could potentially explain our results and may deserve further attention. More research
into the identification of specific groups where vaccination is effectively preventing exacerbations in
COPD patients is needed.
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